Stefano Pierini’s team highlighted that combining CAR-M with an anti-PD-1 antibody in preclinical models significantly inhibited tumor progression, prolonged survival, and remodeled the tumor microenvironment in HER2-positive solid tumors with limited response to PD-1 monotherapy [56]. Here, ERBB2 is linked to neoplasm.